Published in Proteins on December 01, 1993
Conformations of immunoglobulin hypervariable regions. Nature (1990) 5.31
Characterization of the products of DNA-directed DNA polymerases in oncogenic RNA viruses. Nature (1970) 5.23
DNA-directed DNA polymerase activity in oncogenic RNA viruses. Nature (1970) 4.81
Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A. J Mol Biol (1986) 4.16
Synthetic DNA-RNA hybrids and RNA-RNA duplexes as templates for the polymerases of the oncogenic RNA viruses. Nature (1970) 3.98
The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin Fab and the nature of the antigen binding site. Proc Natl Acad Sci U S A (1974) 3.92
Antibody-antigen complexes. Annu Rev Biochem (1990) 3.91
Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma (1984) 3.74
Simultaneous detection of reverse transcriptase and high molecular weight RNA unique to oncogenic RNA viruses. Science (1971) 3.68
Three-dimensional structure of the tryptophan synthase alpha 2 beta 2 multienzyme complex from Salmonella typhimurium. J Biol Chem (1988) 3.52
Three-dimensional structure of an antibody-antigen complex. Proc Natl Acad Sci U S A (1987) 3.48
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res (1992) 2.83
Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst (1995) 2.47
Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res (1983) 2.46
Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A (1994) 2.44
Phenotypic mixing between N- and B-tropic murine leukemia viruses: infectious particles with dual sensitivity to Fv-1 restriction. Cell (1976) 2.34
A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res (1999) 2.33
Presence in human breast cancer of RNA homologous to mouse mammary tumour virus RNA. Nature (1972) 2.31
Major pol gene progenitors in the evolution of oncoviruses. Science (1984) 2.28
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 2.28
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res (2001) 2.01
A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci U S A (1981) 2.00
Three-dimensional structure of immunoglobulins. Annu Rev Biochem (1975) 1.99
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 1.92
In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst (1997) 1.92
Mutant of B-tropic murine leukemia virus synthesizing an altered polymerase molecule. J Virol (1979) 1.90
A new class of endogenous human retroviral genomes. Science (1985) 1.89
Mutations affecting the regulation of production of the enzymes of leucine synthesis in Neurospora. Genetics (1970) 1.86
Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res (1986) 1.86
Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. Proc Natl Acad Sci U S A (1980) 1.86
Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst (2000) 1.85
Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res (1986) 1.84
Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action. Proc Natl Acad Sci U S A (1987) 1.82
Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol (2001) 1.80
Evidence for translation of viral-specific RNA in cells of a mouse mammary carcinoma. Proc Natl Acad Sci U S A (1972) 1.76
Detection and cloning of human DNA sequences related to the mouse mammary tumor virus genome. Proc Natl Acad Sci U S A (1982) 1.74
Antibody-antigen complexes. J Biol Chem (1988) 1.69
DNA polymerase activities in varions of visna virus, a causative agent of a "slow" neurological disease. Proc Natl Acad Sci U S A (1971) 1.67
Structural basis for the specificity of phosphorylcholine-binding immunoglobulins. Immunochemistry (1976) 1.63
RNA-dependent DNA polymerase activity in virus-like particles isolated from human milk. Nature (1971) 1.63
Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases. Nature (1984) 1.62
In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst (1990) 1.61
Structure at 4.5 A resolution of a phosphorylcholine-binding fab. Nat New Biol (1973) 1.60
Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res (1991) 1.60
Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst (1992) 1.59
DNA polymerase activities and nucleic acid components of virions isolated from a spontaneous mammary carcinoma from a rhesus monkey. Proc Natl Acad Sci U S A (1971) 1.57
Model-building studies of antigen-binding sites: the hapten-binding site of mopc-315. Cold Spring Harb Symp Quant Biol (1977) 1.54
Donation of N- or B-tropic phenotype to NB-tropic murine leukemia virus during mixed infections. J Virol (1977) 1.52
Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol (2001) 1.52
Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. Cancer Res (1986) 1.52
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res (2000) 1.52
Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther (1999) 1.52
Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res (2001) 1.51
Activation of a novel calcium-dependent protein-tyrosine kinase. Correlation with c-Jun N-terminal kinase but not mitogen-activated protein kinase activation. J Biol Chem (1996) 1.50
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med (1992) 1.49
A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer (1982) 1.47
Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex. J Exp Med (1992) 1.43
Structure and refinement at 1.8 A resolution of the aspartic proteinase from Rhizopus chinensis. J Mol Biol (1987) 1.43
Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res (1991) 1.41
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med (1990) 1.41
Isolation of the mouse mammary tumor virus sequences not transmitted as germinal provirus in the C3H and RIII mouse strains. J Virol (1977) 1.39
Expression of laminin receptor in normal and carcinomatous human tissues as defined by a monoclonal antibody. Cancer Res (1985) 1.37
Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res (2001) 1.35
Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res (1985) 1.35
Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother (2000) 1.35
Expression of ras oncogene p21 in prostate cancer. N Engl J Med (1986) 1.35
Crystals of phosphorylcholine-binding Fab-fragments from mouse myeloma proteins: preparation and x-ray analysis. Proc Natl Acad Sci U S A (1972) 1.34
Virus-related RNA in human and mouse mammary tumors. J Natl Cancer Inst (1972) 1.34
Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res (1997) 1.34
Monoclonal antibodies to the human laminin receptor recognize structurally distinct sites. Exp Cell Res (1985) 1.32
Relationship in nucleic acid sequences between mouse mammary tumor virus variants. Proc Natl Acad Sci U S A (1975) 1.32
Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. Proc Natl Acad Sci U S A (1984) 1.32
A biochemical approach to the study of the transmission of mouse mammary tumor viruses in mouse strains RIII and C3H. Int J Cancer (1976) 1.30
A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res (1999) 1.28
Detection of high-molecular-weight RNA in particles from human milk. Science (1972) 1.27
ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma. J Exp Med (1985) 1.26
A three-dimensional finite element analysis of the combined behavior of ligaments and menisci in the healthy human knee joint. J Biomech (2005) 1.25
Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine (1997) 1.24
Expression in COS cells of a mouse-human chimaeric B72.3 antibody. Protein Eng (1987) 1.23
Biochemical properties of the bromodeoxyuridine-induced guinea pig virus. J Virol (1975) 1.22
Refined crystal structure of deoxyhemoglobin S. II. Molecular interactions in the crystal. J Biol Chem (1985) 1.22
Quantitation of RNA tumor viruses and viruslike particles in human milk by hybridization to polyadenylic acid sequences. Science (1973) 1.21
Independent polypeptide chain initiation sites for the synthesis of different classes of proteins for an RNA tumor virus: mouse mammary tumor virus. Virology (1976) 1.20
A comparative study of the biologic and molecular basis of murine mammary carcinoma: a model for human breast cancer. J Natl Cancer Inst (1973) 1.19
Structural basis for the specificity of antibody-antigen reactions and structural mechanisms for the diversification of antigen-binding specificities. Q Rev Biophys (1977) 1.19
Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res (1999) 1.17
Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res (1989) 1.16
Type-specific antigenic determinants on the major external glycoprotein of high- and low-oncogenic murine mammary tumor viruses. J Virol (1977) 1.16
A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother (1999) 1.16
Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol (2011) 1.15
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res (1999) 1.15
Radioimmunoassays that demonstrate type-specific and group-specific antigenic reactivities for the major internal structural protein of murine mammary tumor viruses. Cancer Res (1978) 1.15
A finite element model to accurately predict real deformations of the breast. Med Eng Phys (2008) 1.14
Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Res (1983) 1.13
Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer (1983) 1.13
H-2Dd exploits a four residue peptide binding motif. J Exp Med (1993) 1.13